Corporate Spotlight

Cardinal Health and Telix Launch Gallium Awareness Campaign

Dublin (Ohio) and Indianapolis (Indiana) – 27 May 2021. Cardinal Health and Telix launch gallium awareness campaign with release of a white-paper entitled: “Moving beyond the Myth”.

In collaboration with Cardinal Health, Telix is pleased to announce the launch of a gallium awareness campaign with the release of an in-depth white-paper entitled: “Moving beyond the Myth”.

As interest and demand for more accurate prostate cancer imaging grows, and with the approval of the first Ga-68 PSMA based prostate imaging agent late last year, Cardinal Health Nuclear & Precision Health Solutions (Cardinal Health) and Telix Pharmaceuticals (US) Inc. (Telix) have developed an in-depth white-paper, entitled: “Moving beyond the Myth: Meeting the growing demand for Ga-68 radiopharmaceuticals.” The paper shines a light on the pathways for radio-isotope production, distribution and clinical application, as well as highlighting the extensive systems already in place to help ensure potential demand for Ga-68 imaging products is met.

Telix Chief Executive Officer, Dr. Christian Behrenbruch stated,There is a perception in the industry that supply chain issues may limit the availability of gallium-based radiopharmaceuticals. Whilst this may have been true historically, this is no longer the case. The strength and power of gallium lies in its flexibility of production by either cyclotron or generator, offering greater opportunity for scale than other purely cyclotron-based isotopes. Subject to regulator approval, we look forward to offering state-of-the-art diagnostic imaging to U.S. men living with prostate cancer, and Cardinal Health’s radiopharmacy network and infrastructure will be vital in facilitating nationwide access.”

Cardinal Health President, Tiffany Olson added, “Patient and physician satisfaction is our top priority. Telix Pharmaceuticals is developing gallium-based innovations to advance prostate cancer imaging, and Cardinal Health is ready to help meet that demand.”

To read the full media release, please click here.

The white-paper is available for free download here.

To return to Telix’s homepage please click here.

More Articles

ASX News

Telix Update on FDA New Drug Application Review for Illuccix®

Melbourne (Australia) and Indianapolis, IN (U.S.A.) – 17 June 2021. Telix announces participation in a late-cycle meeting with the U.S....

Corporate Spotlight

Telix Pharmaceuticals and Applied Radiology launch TelixU Medical Education Platform Focused on Radiopharmaceutical Research

MELBOURNE, Australia and INDIANAPOLIS 14 June, 2021 – Telix announces the launch of a new educational platform focused on radiopharmaceutical...

Corporate Spotlight

Telix launches “Gallium Wave” Awareness Website

Melbourne (Australia) and Indianapolis (U.S.A.) – 11 June 2021. Telix announces the launch of a new website “Gallium Wave”, as...

Corporate Spotlight

Scott Law joins Telix as SVP Global Manufacturing Operations

11 June 2021 – Corporate Spotlight | Scott Law joins Telix as Senior Vice President Global Manufacturing Operations

ASX News

Telix and ATS Awarded $1.56M ‘Eurostars’ Grant for Alpha Therapy

Liège (Belgium) and Gothenburg (Sweden) – 7 June 2021. Advanced Nuclear Medicine Ingredients S.A, a wholly owned European subsidiary of...

ASX News

Telix and Eckert & Ziegler Sign US Co-Promotion Agreement for Prostate Cancer Imaging

Melbourne (Australia) and Indianapolis, IN (U.S.A.) – 3 June 2021. Telix announces co-promotion agreement with EZAG for Telix’s investigational prostate...

Corporate Spotlight

Cardinal Health and Telix Launch Gallium Awareness Campaign

Dublin (Ohio) and Indianapolis (Indiana) – 27 May 2021. Cardinal Health and Telix launch gallium awareness campaign with release of...

ASX News

TLX66 Meets Study Objectives in Patients with AL Amyloidosis

Melbourne (Australia) and Southampton (United Kingdom) – 25 May 2021. Telix announces bone marrow conditioning investigational candidate TLX66 has met...

ASX News

First Patient Dosed in Japanese Prostate Cancer Imaging Study

Melbourne (Australia) and Kyoto (Japan) – 25 May 2021. Telix announces the first patient has been dosed in a clinical...

ASX News

Telix Pharmaceuticals and Eckert & Ziegler Sign German Distribution Agreement for Prostate Cancer Imaging

Melbourne (Australia) and Berlin (Germany) – 18 May 2021. Telix has entered an exclusive commercial distribution agreement with Eckert &...

Corporate Spotlight

Telix at ANZSNM Annual Scientific Meeting

13 May 2021 – Clinical Spotlight | Telix to Sponsor Pre-Conference Symposium at 51st Australian and New Zealand Society of...

ASX News

Telix Pharmaceuticals Limited AGM 2021 – Chairman and CEO Addresses

Melbourne (Australia) 12 May 2021 – Telix provides the Chairman’s Address and the CEO’s Presentation to the Annual General Meeting...

ASX News

Telix and Monrol Expand Alliance to Include Lutetium Supply

Melbourne (Australia) and Istanbul (Turkey) – 11 May 2021. Telix announces global clinical supply agreement with Monrol for the supply...

ASX News

Telix Commences Phase III Clinical Trial of Prostate Cancer Therapy

Melbourne (Australia) – 10 May 2021. Telix has been granted HREC approval and received CTN clearance by the TGA to...

ASX News

Telix Announces Executive Leadership Appointments and Establishment of Asia Pacific Operating Region

Melbourne (Australia) – 3 May 2021. Telix announces several key executive leadership appointments, including the establishment of an Asia-Pacific (APAC)...

ASX News

Telix Pharmaceuticals Appoints Richard Valeix as EMEA President

Melbourne (Australia) and Herstal (Belgium) – 3 May 2021. Telix announces Richard Valeix has joined the Telix executive leadership team...

ASX News

Telix Pharmaceuticals and Global Medical Solutions Complete Strategic Manufacturing Agreement

Melbourne (Australia) and Henderson, NV (U.S.A.) – 27 April 2021. Telix announces it has completed a strategic manufacturing agreement with...

ASX News

Japanese Renal Cancer Imaging Trial Meets Study Objectives

Melbourne (Australia) and Kyoto (Japan) – 21 April 2021. Telix announces the Company’s ZIRDAC-JP study of its renal cancer imaging...

ASX News

Launch of the International NOBLE Registry of Telix’s SPECT-Based Prostate Cancer Imaging Agent

Melbourne (Australia) and Brussels (Belgium) – 19 April 2021. Telix announces the launch of the international NOBLE Registry of Telix’s...

ASX News

Telix Pharmaceuticals Limited – Notice of Annual General Meeting 2021

Melbourne (Australia) – 12 April 2021. Telix Pharmaceuticals provides notice of The Annual General Meeting of Shareholders on Wednesday 12...

ASX News

Telix Pharmaceuticals and Grand River Aseptic Manufacturing Complete Agreement for Commercial Manufacturing of Illuccix®

Melbourne (Australia) and Indianapolis, IN (U.S.A.) – 31st March 2021. Telix announces it has completed an agreement with Grand River...

Corporate Spotlight

Telix Appoints Darren Patti, Chief Operating Officer, Telix Pharmaceuticals (US) Inc.

29th March 2021 – Corporate Spotlight | Darren Patti joins Telix as Chief Operating Officer, Telix Pharmaceuticals (US) Inc.

ASX News

Telix Pharmaceuticals and ITM Complete Global Agreements for Lutetium-177 Radioisotope Supply

Melbourne (Australia) and Garching (Germany) – 18th March 2021. Telix announces it has extended its non-exclusive global clinical and commercial supply...

Corporate Spotlight

Telix Appoints Sébastien Linard as General Manager, Telix European Manufacturing Facility

8th March 2021 – Corporate Spotlight | Sébastien Linard joins Telix as General Manager of Telix’s European Manufacturing in Seneffe,...

ASX News

Telix Pharmaceuticals and ITM Complete Global Agreements for Lutetium-177 Radioisotope Supply

Melbourne (Australia) and Garching (Germany) – 18th March 2021. Telix announces it has extended its non-exclusive global clinical and commercial...

ASX News

Telix Pharmaceuticals Releases Results for the Year Ended 31 December 2020 and 2020 Annual Report

Melbourne (Australia) – 26th February 2021. Telix Pharmaceuticals Limited Releases Full-Year 2020 Results and 2020 Annual Report.

ASX News

Telix and Kanazawa University Cleared to Commence Prostate Cancer Imaging Study in Japan

Melbourne (Australia) and Kyoto (Japan) – 22nd February 2021. Telix Japan receives Clinical Trial Notification (CTN) clearance to commence a...

ASX News

Telix FY2020 Results and Company Update Conference Call

Melbourne (Australia) – 16th February 2021. Telix to present the Company’s FY2020 results together with an update on Telix’s operations.

ASX News

Czech Republic Grants National Authorisation for the Use of Telix’s Prostate Cancer Imaging Product

Melbourne (Australia) and Liège (Belgium) – 16th February 2021. Telix announces the Ministry of Health of the Czech Republic is...

ASX News

Telix and Heidelberg University Hospital to Develop Next Generation Theranostics

Melbourne (Australia) and Heidelberg (Germany) – 10th February 2021. Telix announces research cooperation agreement with Heidelberg University Hospital to develop...

Corporate Spotlight

Industry Leaders’ Round-Table at SNMMI Mid-Winter Satellite Symposium

3rd February 2021 | Corporate Spotlight – Recording of Industry Leaders’ Round-Table Discussion at SNMMI Mid-Winter Symposium: Ga-68 PSMA-11: Advances...

ASX News

First U.S. Patients Dosed in Phase III ZIRCON Trial of Renal Cancer Imaging Product

Melbourne (Australia) and Indianapolis, IN (U.S.A.) – 25th January 2021. Telix Pharmaceuticals announces the first U.S. patients have been dosed...

Corporate Spotlight

ARTMS and Telix Pharmaceuticals Announce Successful Production of 68Ga PSMA-11 with Cyclotron Produced 68Ga from a Solid Target

Burnaby, Canada and Indianapolis, USA, January 12, 2021 – ARTMS Inc. and Telix announce successful production of Telix’s prostate cancer...

ASX News

Telix Pharmaceuticals Files New Drug Submission with Health Canada for Prostate Cancer Imaging Product

Melbourne (Australia) and Indianapolis, IN (USA) – 16th December 2020. Telix has filed a New Drug Submission (NDS) with Health Canada...

ASX News

Telix Pharmaceuticals and Mauna Kea Technologies Launch Urologic Oncology Alliance

Melbourne (Australia) – 16th December 2020. [Article updated with new video 16th February 2021] Telix Pharmaceuticals announces collaboration with Mauna...

ASX News

Telix and Kanazawa University Commence Japanese Clinical Study for Prostate Cancer Imaging

Melbourne (Australia) – 14th December 2020. Telix announces its subsidiary, Telix Pharmaceuticals Japan KK, has entered a clinical study collaboration...

ASX News

Telix Completes IP Agreement with the University of Southampton (UK) Granting Exclusive Access to TRALA Clinical Trial Data

Melbourne (Australia) – 14th December 2020. Telix Pharmaceuticals Limited announces today that its wholly-owned subsidiary TheraPharm GmbH has completed an...

ASX News

Telix Granted TGA Priority Review for Prostate Cancer Imaging

Melbourne (Australia) – 7th December 2020. Telix has been granted Priority Review status for TLX591-CDx (68Ga-PSMA-11), a radiopharmaceutical for the...

ASX News

Telix and DuChemBio Announce Korean Partnership for Advanced Prostate Cancer Imaging

Melbourne (Australia) and Seoul (South Korea) – 3rd December 2020. Telix Pharmaceuticals announces it has entered into a licensing and partnership...